A cerebrospinal fluid analysis of amyloid, total tau, and phospho-tau181 levels supported a clinical diagnosis of dementia due to AD and was consistent with CNS amyloid accumulation (A+/T+/N+ in the AD biomarker classification scheme). The gene discussed is MAPT; the disease is Alzheimer disease.